Morgan Stanley analysts sat in a room and decided Korean beauty products will hit $4 billion in U.S. sales by 2026. They published this forecast. Retail traders saw the number and immediately started googling which penny stocks sell snail mucin.
K-beauty is becoming mainstream. That's the headline. Mainstream means your aunt in Ohio now owns something with fermented yeast extract in it. She doesn't know what fermented yeast extract does. She bought it because a teenager on TikTok said it would fix her pores. Her pores remain unchanged.
The forecast assumes even more growth ahead. More growth in an industry that convinces Americans to put essence on their face before serum, then serum before ampoule, then ampoule before moisturizer. That's four separate products before you leave the bathroom. Koreans invented a skincare routine so complicated it requires a flowchart and Americans looked at it and said yes, this is exactly what my life was missing.
$4 billion by 2026. That's next year. Morgan Stanley believes Americans will spend $4 billion on products with ingredient lists that read like a Pokemon roster. Centella asiatica. Propolis. Ginseng root extract. Retail traders will see this report and buy shares in whatever company makes sheet masks, unaware that sheet masks have the profit margin of a gas station sandwich.
The technical analysis on K-beauty stocks is irrelevant. The chart doesn't care that your girlfriend owns seven different sleeping packs. Support and resistance levels don't change because some analyst decided Korean sunscreen is the future. But retail traders will buy anyway, convinced they've discovered the next big thing, only to watch their portfolio melt faster than a clay mask under hot water.
By 2027, Morgan Stanley will publish a new forecast explaining why K-beauty sales missed expectations, and your aunt in Ohio will still be trying to figure out what the hell a pH-balancing toner actually does.
Photo by Felicia Buitenwerf on Unsplash
Leave a Comment